Article
Sensitivity, specificity, and accuracy of molecular profiling on circulating cell-free DNA in refractory or relapsed multiple myeloma patients, results of MM-EP1 study.
Leukemia & lymphoma - 1 Jun 2024
Quivoron C, Michot J-M, Danu A, Lecourt H, Saada V, Saleh K, Vergé V, Cotteret S, Bernard O A, Ribrag V
Abstract excerpt
As a promising alternative to bone marrow aspiration (BMA), mutational profiling on blood-derived circulating cell-free tumor DNA (cfDNA) is a harmless and simple technique to monitor molecular response and treatment resistance of patients with refractory/relapsed multiple myeloma (R/R MM). We evaluated the sensitivity and specificity of cfDNA compared to BMA CD138 positive myeloma plasma cells (PCs) in a series...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.